Hemanext Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-31.
Hemanext Inc. filed a Form D notice of an exempt securities offering with the SEC on July 31, 2025. The filing reports $21.71M sold. Its industry group is Other Health Care. It names Andrew Dunham (President, Chief Executive Officer, and Member of the Board of Directors), Eric Newman (Vice President, Chief Financial Officer, and Corporate Secretary), Laurel Omert (Chief Medical Officer) (SEC Form D, July 31, 2025).
Is this your company?
Sell to companies like Hemanext Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-31 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Hemanext Inc.
Free to see. No signup.
More on the people and the money behind Hemanext Inc., from the filings we hold.
Other Health Care raises by companies based in Massachusetts, filed in July 2025, largest first.
Get an email when Hemanext Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Hemanext Inc. raises, hires or launches. No email unless you switch it on.
Watch Hemanext Inc. →Get the full cited report on Hemanext Inc.
What the filing shows about Hemanext Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Hemanext Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Hemanext Inc.'s address as 99 Hayden Avenue, Building B, Suite 620, Lexington, MA 02421.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Hemanext Inc. is a registered filer with the SEC (CIK 1305849) and has filed since 2023-02-07. 5 filings are on record, the latest on 2025-08-05.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Hemanext Inc.'s Form D of 2025-07-31 names Andrew Dunham, Eric Newman, Laurel Omert and 13 more as its officers, directors or promoters.
Its new offerings report $71.23M sold across 5 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 869 filings in Other Health Care, totalled by week.
On the filing as: Executive Officer, Director.
Andrew Dunham is named as President, Chief Executive Officer, and Member of the Board of Directors on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Eric Newman is named as Vice President, Chief Financial Officer, and Corporate Secretary on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Laurel Omert is named as Chief Medical Officer on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Laura Daniels is named as Vice President of Product Development on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Robert Haime is named as Vice President of Commercial Operations on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Jill Buckley is named as Vice President of Human Resources on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Director.
Stephen Eckert is named as Chairman of the Board of Directors on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Peter Testa is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
William O'Neill is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Eduardo Avayu is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Paul Ness is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
On the filing as: Executive Officer.
Daan Kok is named as Head of Business Development and Strategy on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Ismail Kola is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Geoffrey Crouse is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Philip Pead is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
Joseph Grogan is named as Director on the Form D that Hemanext Inc. filed with the SEC on 31 July 2025, one of 16 people that filing names.
16 people named on the filing — 7 holding an executive role and 9 as directors only.
Named as of the 2025-07-31 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 16 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Hemanext Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Hemanext Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hemanext Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Hemanext Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Hemanext Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Hemanext Inc.. With no account yet, you sign up free and land on the result.
On these lists: Health care raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/hemanext-inc-form-d-25000001